Edition:
United Kingdom

IP Group PLC (IPO.L)

IPO.L on London Stock Exchange

95.80GBp
4:39pm BST
Change (% chg)

-1.10 (-1.14%)
Prev Close
96.90
Open
95.70
Day's High
97.30
Day's Low
93.30
Volume
376,116
Avg. Vol
580,754
52-wk High
145.60
52-wk Low
84.61

Summary

Name Age Since Current Position

Douglas Flint

62 2018 Non-Executive Chairman of the Board

Alan Aubrey

56 2006 Chief Executive Officer, Executive Director

Greg Smith

39 2011 Chief Financial Officer, Executive Director

David Baynes

55 2014 Chief Operating Officer, Executive Director

Michael Townend

55 2011 Chief Investment Officer, Executive Director

Angela Leach

2008 Company Secretary

David Begg

67 2018 Senior Non-Executive Independent Director

Jonathan Brooks

62 2011 Non-Executive Independent Director

Lynn Gladden

56 2014 Non-Executive Independent Director

Elaine Sullivan

57 2015 Non-Executive Independent Director

Biographies

Name Description

Douglas Flint

Sir Douglas J. Flint, CBE is Non-Executive Chairman of the Board of the Company, with effect from 01 November 2018. Sir Douglas retired as Group Chairman of HSBC Holdings plc on 30th September 2017, having been appointed to that role in December 2010. For fifteen years prior to this he was HSBC's Group Finance Director, joining from KPMG where he was a partner. Between 2005 and 2011 he was also a Non-Executive Director of BP plc. Mr Flint was Chairman of the Institute of International Finance from June 2012 to December 2016 and was a member of both the Mayor of Beijing's and the Mayor of Shanghai's International Business Leaders' Advisory Councils. Amongst other roles he is currently Chairman of the Archbishop of Canterbury's Just Finance Foundation, a Director of the Centre for Policy Studies, on the Global Advisory Council of Motive Partners, a fintech specialist investment platform, Chairman of the Corporate Board of Cancer Research UK and a Trustee of the Royal Marsden Cancer Charity. In December 2017 he was appointed by the Chancellor as Special Envoy to China's Belt and Road Initiative.

Alan Aubrey

Mr. Alan John Aubrey is Chief Executive Officer, Executive Director of IP Group Plc. He co-founded Techtran Group Limited in 2002 and was its CEO when the business was acquired by IP Group in January 2005. Previously he was a partner in KPMG where he specialised in corporate finance advice to technology-based fast growth businesses and has an experience in helping them raise money and prepare for sale or flotation. Alan joined the Board of IP Group in January 2005, becoming Chief Executive on 1 January 2006 and has overall responsibility for the operational management of the Group. He is also a chairman of the Department for Business, Innovation & Skills (“BIS”) audit and risk committee.

Greg Smith

Mr. Greg Smith ACA., is Chief Financial Officer, Executive Director of IP Group plc., since June 3, 2011. He joined IP Group in January 2008 and was appointed Chief Financial Officer in June 2011. Previously Greg spent three years at Tarchon Capital Management, a multi-billion dollar fund of hedge funds business where he had day-to-day responsibility for building and managing the operations and accounting team as well as external operational due diligence on investee hedge funds. Prior to Tarchon, Greg spent four years in KPMG’s London Financial Services practice working with asset management, insurance and banking clients. Greg is Chartered Accountant and holds a degree in mathematics from the University of Warwick.

David Baynes

Mr. David Baynes is Chief Operating Officer, Director of IP Group PLC. David, who was previously a Chief Executive Officer of Fusion IP plc ("Fusion IP"), was appointed to IP Group's Board upon completion of the Group's acquisition of Fusion IP last month.

Michael Townend

Mr. Michael Charles Nettleton Townend is Chief Investment Officer, Executive Director of IP Group Plc. He was formerly managing director within the European Equities business of Lehman Brothers with responsibility for equity sales to hedge funds. Mike has over 17 years of experience in all aspects of equity capital markets. Mike was appointed a director of IP Group in March 2007.

Angela Leach

David Begg

Prof. David Knox Houston Begg is Senior Non-Executive Independent Director of the Company. Experience - Professor of Economics at Imperial College London, Principal of Imperial College Business School 2003-2011. Previous appointments include Professor of Economics at Birkbeck College, Visiting Fellow at the Reserve Bank of Australia and Visiting Professor at M.I.T and acting as an economic policy advisor to the Bank of England.

Jonathan Brooks

Mr. Jonathan Brooks is Non-Executive Independent Director of IP Group plc., since 31 August 2011. He was the chief financial officer of ARM Holdings plc from 1995 until 2002 where he was responsible for finance, investor relations, legal and IT, and where he managed the dual-listed IPO process of ARM on the London Stock Exchange and Nasdaq in 1998. He is a non-executive director of Aveva Group plc, a provider of engineering data and design IT systems, and chairman of Nasdaq-listed Xyratex Ltd, a provider of data storage systems. He joined IP Group’s Board in 2011 and is also Chairman of the Group’s Audit Committee.

Lynn Gladden

Prof. Lynn Gladden, CBE is Non-Executive Independent Director of IP Group PLC. She is Pro-Vice-Chancellor for Research for the University of Cambridge, the Shell Professor of Chemical Engineering and the former Head of the Department of Chemical Engineering and Biotechnology. Professor Gladden serves as a Director of Cambridge Enterprise Limited, is a former member of the Council of the Engineering and Physical Sciences Research Council (EPSRC) and, in 2013, she was appointed to the Shell Science Council. She was Science Advisor to Unilever from 1998 - 2006 and a Senior Consultant to Physical & Engineering Sciences at Unilever from 2006-2008. She is a Fellow of the Royal Society, the Royal Academy of Engineering, the Institution of Chemical Engineers, the Royal Society of Chemistry and the Institute of Physics and is a chartered engineer and chartered chemist. Professor Gladden leads the activities at the Magnetic Resonance Research Centre at the University of Cambridge and has a particular interest in applying magnetic resonance imaging techniques in the fields of heterogeneous catalysis and multi-phase transport in porous media. She is a Fellow of Trinity College. She was awarded the 2014 Bakerian Lecture of the Royal Society and, in 2001, the Tilden lectureship and silver medal of the Royal Society of Chemistry. In 1996, she was awarded a Miller Visiting Professorship at the University of California, Berkeley and she received the Beilby Medal and Prize from the Royal Society of Chemistry in 1995. In 2013, Professor Gladden was awarded an Honorary Doctorate of Science from the University of Bristol and in 2009 she was awarded a CBE for services to chemical engineering following an OBE for services to chemistry in 2001.

Elaine Sullivan

Dr. Elaine Sullivan is Non-Executive Independent Director of IP Group Plc., with effect from 30 July 2015. Dr Sullivan has over 25 years of international experience working in the pharmaceutical industry and was a member of the senior management teams in R&D at Eli Lilly and AstraZeneca. She has developed new molecules in therapy areas including virology, cancer, ophthalmology, respiratory and inflammation. In 2015, she founded a specialist oncology company, Carrick Therapeutics, and holds the position of Chief Executive. From 2011 to 2015, Dr Sullivan was Vice President Global External Research & Development in the US for Eli Lilly, where she led a global workforce delivering access to business critical external innovation. Global External R&D included the search and evaluation function and Chorus, the virtual early phase drug development arm. She was also a member of the Investment Committees of Lilly Ventures and Lilly Asian Ventures and a member of the Steering Committees of Lilly's Capital Fund Partners. Dr Sullivan spent over 15 years at AstraZeneca, where she held a number of roles including Vice President, Science & Technology. During this period, she identified and established novel drug-hunting approaches from target to delivery of proof of concept, which successfully reduced compound attrition in the clinic and significantly decreased the time to deliver new molecules. She also held the position of Vice President, R&D New Opportunities, establishing and leading the first virtual Therapy Area in AstraZeneca. New Opportunities pinpointed new disease areas and future healthcare trends, created new therapeutic applications for multiple molecular entities and advanced them into the clinic. Dr Sullivan has a BSc (Hons) in Molecular Biology from the University of Glasgow and a PhD in Molecular Virology from the University of Edinburgh. In June 2015, Dr Sullivan was appointed to the Supervisory Board of Evotec AG, a drug discovery solutions company.

Basic Compensation

Name Fiscal Year Total

Douglas Flint

--

Alan Aubrey

552,000

Greg Smith

443,000

David Baynes

452,000

Michael Townend

446,000

Angela Leach

--

David Begg

9,000

Jonathan Brooks

57,000

Lynn Gladden

42,000

Elaine Sullivan

58,000
As Of  31 Dec 2017